Mackay Shields LLC Neurocrine Biosciences Inc Transaction History

Mackay Shields LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$89.43 - $102.27 $693,529 - $793,103	-7,755 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $1.47 Million - $1.83 Million	-16,857 Reduced 68.49%	7,755 $743,000
Q3 2020 Nov 04, 2020	SELL	$96.16 - $135.15 $811,301 - $1.14 Million	-8,437 Reduced 25.53%	24,612 $2.37 Million
Q2 2020 Jul 31, 2020	SELL	$85.09 - $130.36 $694,164 - $1.06 Million	-8,158 Reduced 19.8%	33,049 $4.03 Million
Q1 2020 May 08, 2020	SELL	$75.11 - $113.76 $1.26 Billion - $1.91 Billion	-16,819,205 Reduced 99.76%	41,207 $3.57 Million
Q1 2019 May 13, 2019	BUY	$69.31 - $91.53 $1.17 Billion - $1.54 Billion	16,842,640 Added 94770.65%	16,860,412 $23 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $1.21 Million - $2.21 Million	17,772 New	17,772 $1.27 Million

642

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.